GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeNeuro SA (XPAR:GNRO) » Definitions » Loans Receivable

GeNeuro (XPAR:GNRO) Loans Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is GeNeuro Loans Receivable?

GeNeuro's Loans Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


GeNeuro Loans Receivable Historical Data

The historical data trend for GeNeuro's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeNeuro Loans Receivable Chart

GeNeuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GeNeuro Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GeNeuro Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


GeNeuro Loans Receivable Related Terms

Thank you for viewing the detailed overview of GeNeuro's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


GeNeuro Business Description

Traded in Other Exchanges
Address
3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).

GeNeuro Headlines

No Headlines